Valuation: AbbVie Inc.

Market Cap 450B 394B 364B 336B 638B 42,987B 649B 4,358B 1,696B 21,078B 1,689B 1,652B 73,147B P/E 2026 *
30.7x
P/E 2027 * 23.9x
Enterprise Value 505B 442B 408B 377B 715B 48,239B 728B 4,891B 1,903B 23,653B 1,896B 1,854B 82,083B EV / Sales 2026 *
7.51x
EV / Sales 2027 * 6.82x
Free-Float
95.71%
Yield 2026 *
2.7%
Yield 2027 * 2.84%
1 day-0.75%
1 week+0.44%
Current month+0.44%
1 month+11.23%
3 months+22.47%
6 months+8.28%
Current year+10.61%
1 week 250.51
Extreme 250.51
261.64
1 month 215.37
Extreme 215.37
261.64
Current year 190.75
Extreme 190.75
261.64
1 year 184.63
Extreme 184.63
261.64
3 years 132.7
Extreme 132.7
261.64
5 years 105.56
Extreme 105.56
261.64
10 years 55.06
Extreme 55.0623
261.64
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Director

62 0.0000%
06-29Free

Director

134 0.0000%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%+0.44%+34.70%+86.52% 450B
-1.60%+1.37%+57.31%+168.94% 1,102B
-1.44%+3.71%+69.64%+65.40% 643B
-1.35%+0.63%+30.26%+26.28% 336B
-0.86%+0.99%+39.36%+40.85% 298B
-0.71%-0.54%+28.98%+48.27% 288B
-1.31%+2.72%-26.76%-39.82% 222B
-0.03%+1.62%+25.62%+68.30% 199B
-0.40%+7.50%+21.51%+82.50% 169B
-0.08%-0.12%-4.71%-32.31% 137B
Average -0.67%+2.22%+27.59%+51.49% 384.32B
Weighted average by Cap. -0.47%+2.06%+40.58%+82.30%

Financials

2026 *2027 *
Net sales 67.24B 58.9B 54.35B 50.22B 95.29B 6,425B 97.02B 651B 253B 3,150B 252B 247B 10,932B 72.74B 63.71B 58.79B 54.33B 103B 6,950B 105B 705B 274B 3,408B 273B 267B 11,826B
Net income 14.35B 12.57B 11.6B 10.72B 20.34B 1,371B 20.71B 139B 54.1B 672B 53.9B 52.72B 2,334B 19.02B 16.66B 15.37B 14.21B 26.96B 1,818B 27.45B 184B 71.71B 891B 71.43B 69.87B 3,093B
Net Debt 54.97B 48.15B 44.42B 41.05B 77.9B 5,252B 79.31B 532B 207B 2,575B 206B 202B 8,936B 46.35B 40.6B 37.46B 34.62B 65.69B 4,429B 66.88B 449B 175B 2,171B 174B 170B 7,536B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-08 US$252.74 -0.75% 5,672,044
26-07-07 US$254.65 -0.04% 8,238,267
26-07-06 US$254.76 -2.42% 8,580,220
26-07-02 US$261.07 +3.99% 7,114,422
26-07-01 US$251.06 -0.23% 6,987,982
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
254.65USD
Average target price
258.32USD
Spread / Average Target
+1.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock